Comparison
KPV vs Melanotan II
KPV is healing & repair; Melanotan II is melanocortins. They are compared here because they are frequently considered against each other, not because they act alike.
On published evidence alone, Melanotan II is the better documented of the two (preliminary human). That is a statement about the state of the literature, not a recommendation.
| KPV | Melanotan II | |
|---|---|---|
| Class | Healing & repair | Melanocortins |
| Evidence | Animal models only | Preliminary human |
| Human trials | None published | ~6 |
| Half-life | ~1-2 hours | ~1-2 hours |
| Reported range | 200-500 mcg | 250 mcg - 1 mg |
| Frequency | 1-2x daily | Daily loading then 2-3x weekly maintenance |
| Routes | Oral, Subcutaneous, Topical | Subcutaneous |
| FDA approved | No | No |
| Research use only | Yes | Yes |
| Banned in sport | No | No |
| Studied for | Inflammatory bowel research, Skin inflammation, Gut barrier research | Tanning, Appetite suppression, Erectile function |
| Reported side effects | Injection-site reactions, Mild gastrointestinal upset | Nausea, Facial flushing, Spontaneous erections, Darkening of moles, Appetite loss, Lethargy |
KPV
KPV is the terminal three residues of alpha-melanocyte-stimulating hormone. It retains the parent hormone anti-inflammatory activity, apparently by entering cells and interfering with NF-κB and MAPK signalling to reduce proinflammatory cytokine production, but it does not activate melanocortin-1 receptors and therefore does not cause tanning. Most research is in inflammatory bowel models, where oral and rectal delivery have been examined.
Melanotan II
Melanotan II is a cyclic lactam analog of alpha-melanocyte-stimulating hormone that activates melanocortin receptors non-selectively, including MC1R, MC3R and MC4R. MC1R activation drives melanogenesis and tanning; MC4R activation produces the appetite suppression and the erectile effects that led to the development of the selective derivative bremelanotide. Non-selectivity is precisely the problem: users cannot obtain one effect without the others, and health agencies in several countries have issued warnings about unregulated supply and about melanoma risk from darkening existing naevi.
KPV vs Melanotan II: common questions
What is the difference between KPV and Melanotan II?
KPV is healing & repair and Melanotan II is melanocortins, so they act on different pathways. KPV: The C-terminal tripeptide of alpha-MSH, which keeps the anti-inflammatory activity without the pigmentation effects. Melanotan II: A non-selective melanocortin agonist that causes tanning, appetite suppression and erections. Subject of repeated regulatory warnings.
Which has stronger evidence, KPV or Melanotan II?
Melanotan II has the stronger evidence base (preliminary human, about 6 human studies) compared with KPV (animal models only).
Are KPV and Melanotan II FDA approved?
Neither is FDA approved for any indication.
References
Regulatory and primary sources
- PubChem compound record (CID 13294447) ↗ · structure, identifiers, synonyms
- FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
- PubChem compound record (CID 92432) ↗ · structure, identifiers, synonyms
- CAS Registry Number 121062-08-6 ↗ · chemical identity
Published literature
- The neuroimmunomodulatory peptide alpha-MSH.Ann N Y Acad Sci 2000.PubMed 11268347 · doi:10.1111/j.1749-6632.2000.tb05386.x
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.J Sports Med Phys Fitness 2026.PubMed 41880199 · doi:10.23736/S0022-4707.26.17773-1
- The neuropeptide alpha-MSH in host defense.Ann N Y Acad Sci 2000.PubMed 11268348 · doi:10.1111/j.1749-6632.2000.tb05387.x
- Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.Adv Exp Med Biol 2010.PubMed 21222263 · doi:10.1007/978-1-4419-6354-3_8
- Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.Int J Med Sci 2025.PubMed 41209547 · doi:10.7150/ijms.118118
- Mechanisms of antiinflammatory action of the neuroimmunomodulatory peptide alpha-MSH.Ann N Y Acad Sci 1998.PubMed 9629264 · doi:10.1111/j.1749-6632.1998.tb09576.x
- Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.Drug Discov Today 2025.PubMed 41241376 · doi:10.1016/j.drudis.2025.104535
- Peptide modulation of inflammatory processes within the brain.Neuroimmunomodulation 1998.PubMed 9730684 · doi:10.1159/000026335
- Falsification of biotechnology drugs: current dangers and/or future disasters?.J Pharm Biomed Anal 2018.PubMed 30165334 · doi:10.1016/j.jpba.2018.08.037
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.Peptides 2006.PubMed 16412534 · doi:10.1016/j.peptides.2005.01.029
- Sympathetic and sensory innervation of brown adipose tissue.Int J Obes (Lond) 2010.PubMed 20935665 · doi:10.1038/ijo.2010.182
- Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.Int J Impot Res 2000.PubMed 11035391 · doi:10.1038/sj.ijir.3900582
- Melanotan II: a possible cause of renal infarction: review of the literature and case report.CEN Case Rep 2020.PubMed 31953620 · doi:10.1007/s13730-020-00447-z
- Central nervous system agents in the treatment of erectile dysfunction: how do they work?.Curr Urol Rep 2001.PubMed 12084236 · doi:10.1007/s11934-001-0044-6
- Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.Life Sci 1996.PubMed 8637402 · doi:10.1016/0024-3205(96)00160-9
- Discovery that a melanocortin regulates sexual functions in male and female humans.Peptides 2005.PubMed 15996790 · doi:10.1016/j.peptides.2005.01.023
Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.